Abstract
A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy. The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure. After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis. Urinary volume and serum creatinine levels recovered to the normal range, with urinary protein disappearing completely within 40 days. This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.
Similar content being viewed by others
References
Roger MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(Suppl 12):2961–78.
Lioté F, Boval-Boizard B, Fritz P, Kuntz D. Lymphocyte subsets in pamidronate-induced lymphopenia. Br J Rheumatol. 1995;34:993–5.
Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17:897–907.
Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164–72.
Stratton JD, Warwicker P. Relapse of nephrotic syndrome triggered by bisphosphonates. Nephrol Dial Transplant. 2002;17:1856–7.
Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): A randomized trial. JAMA. 2006;296:2927–38.
de Nijs RNJ, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355:675–84.
Dijkman H, Smeets B, van der Laak J, Steenbergen E, Wetzels J. The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis. Kidney Int. 2005;68:1562–72.
Asano T, Niimura F, Pastan I, Fogo AB, Ichikawa I, Matsusaka T. Permanent genetic tagging of podocytes: Fate of injured podocytes in a mouse model of glomerular sclerosis. J Am Soc Nephrol. 2005;16:2257–62.
Marshall CB, Shankland SJ. Cell cycle and glomerular disease: A minireview. Nephron Exp Nephrol. 2006;102:e39–48.
Pascual J, Torrealba J, Myers J, Tome S, Samaniego M, Musat A, et al. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int. 2007;18:1435–8.
Acknowledgments
This work was supported by a grant (to H.I.) from the Progressive Renal Diseases Research Project of the Ministry of Health, Labour and Welfare of Japan.
Conflict of interest statement
None declared.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Miura, N., Mizuno, N., Aoyama, R. et al. Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis. Clin Exp Nephrol 13, 85–88 (2009). https://doi.org/10.1007/s10157-008-0078-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-008-0078-x